Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.
about
Cholinesterase inhibitors for Alzheimer's diseaseGalantamine for Alzheimer's disease and mild cognitive impairmentGalantamine for vascular cognitive impairmentGalantamine for Alzheimer's diseaseVascular risk factors and dementia: how to move forward?Stroke, dementia, and drug deliveryHemispatial neglectBinswanger's disease: toward a diagnosis agreement and therapeutic approachWhite matter hyperintensities, cognitive impairment and dementia: an update.Ischemic brain injury in cerebral amyloid angiopathyClinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.Donepezil: a clinical review of current and emerging indications.Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials.Cholinesterase inhibitors: drugs looking for a disease?Mild cognitive impairment in stroke patients with ischemic cerebral small-vessel disease: a forerunner of vascular dementia?Promotion of the mind through exercise (PROMoTE): a proof-of-concept randomized controlled trial of aerobic exercise training in older adults with vascular cognitive impairmentCholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment.Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease.The Effects of an Uninterrupted Switch from Donepezil to Galantamine without Dose Titration on Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease.Update on the pharmacological treatment of Alzheimer's diseaseVascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patientsTreatment of dementia with neurotransmission modulation.Preservation of neurons of the nucleus basalis in subcortical ischemic vascular diseasePharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease : A systematic review across modalitiesEffect of acupuncture treatment on vascular cognitive impairment without dementia: study protocol for a randomized controlled trial.Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimenDonepezil in Alzheimer's disease: From conventional trials to pharmacogeneticsClinically tested drugs for Alzheimer's disease.Vascular cognitive impairment: disease mechanisms and therapeutic implications.Is the distinction between Alzheimer's disease and vascular dementia possible and relevant?Diffusion tensor MRI correlates with executive dysfunction in patients with ischaemic leukoaraiosisBrief cognitive assessment for patients with cerebral small vessel disease.Young onset dementiaMasitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.Non-pharmacological interventions in cognitively impaired and demented patients--a comparison with cholinesterase inhibitors.The role of cardiovascular risk factors in Alzheimer's disease.Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease.Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.
P2860
Q22252975-1EBC8D8D-4C20-4A2B-AC49-0AFC555BE4CAQ24244773-5F8B344A-84D7-4556-AA03-CB217236643FQ24244817-7C4DA5BA-7BDE-4BA2-ACE1-2260FA53FB40Q24246158-61027D4B-4B9C-4398-BF2D-A616A1B63C03Q24650263-D0E02E6C-EC40-476B-AFDA-D04B08B929EBQ28166505-DAB506D8-1C68-41BA-AAAA-EDD3AB494B27Q28237312-60C7C7FB-4FF6-4363-840C-85AD75837A6FQ30848732-1A31E963-CFB9-414D-B499-6956C4110FBBQ30893715-0EC2543C-919D-4242-BB20-455ED99859D3Q30945201-0E6E7A3B-F01B-40EE-9D6C-447F16BB6472Q31155412-E95EA6D7-0A56-4E7B-B8F8-1D2FB1107BA3Q33150809-7A86A8C3-BFE6-4ECC-9690-C987BD1FF38FQ33160127-E6F93655-65B8-4021-B738-AB6F5E99EBDEQ33238993-54C80F0D-10EF-486E-AF51-EB31223445E0Q33492926-25E39231-3AA2-4E36-AC9E-80863EA3121BQ33531561-AFE51E64-1372-48B5-B715-F1BCA42C32D6Q33552656-7EBA2AF9-F9A2-403A-A0CB-CCC93650BC58Q33790288-DF15E60B-B901-4C38-946E-4AD85EA64B19Q33795194-7C26F369-4686-468B-A99F-AE75A6D2E97AQ33836947-46688D5C-E19F-45E6-B924-01A9EE3F2251Q33967781-F3FA901C-9C9F-4D59-886B-61A9319151A0Q34038332-93AE1B07-9992-49ED-960D-9DB5DE02A6B5Q34266258-45A9996A-1AAB-44C8-AE71-EDB7FAB71C11Q34287524-5F5F8875-8C43-43F9-AD80-5EF8F0F96312Q34552380-576C3738-30F8-45CB-97E6-01CA6C62FAE7Q34565375-AF6F049E-167C-40E1-9B4F-8C6170067C1BQ34648742-0D2DFA89-CF96-4291-8856-E2665457F48CQ34655353-43A169A9-E020-4AB0-8B23-C7B678671DA2Q34965949-903C7F08-847F-4D2B-99D4-6A115C77F887Q35164747-EF3C1307-739D-470E-8A8C-AA5B6D95FD51Q35197111-2DFBCEA1-F5B6-437C-BC42-52B29DB6DE06Q35236550-DD895822-2C8C-4ACB-AF35-57676AAA41D1Q35479970-F106EA7D-05F5-4FDC-A955-069D0CD2AC00Q35489446-A2ED9C2B-27FD-46C8-A818-8464932FC0F5Q35518978-F7477D73-150C-4B2F-8396-D843C68D2738Q35579238-2046BC6B-89F4-40EA-BFD3-D1A804FA86E6Q35593781-BB465BD0-26FF-42FB-8452-1D7506C438D6Q35618918-FEFD07CD-FF32-484A-879F-03C92F2D33EBQ35748293-44C3BCF0-9AC3-4EFE-8940-C7BD2678077FQ35765716-FEE41996-8E5D-4022-A1E3-1810DE14CD6E
P2860
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Efficacy of galantamine in pro ...... r disease: a randomised trial.
@en
Efficacy of galantamine in pro ...... r disease: a randomised trial.
@nl
type
label
Efficacy of galantamine in pro ...... r disease: a randomised trial.
@en
Efficacy of galantamine in pro ...... r disease: a randomised trial.
@nl
prefLabel
Efficacy of galantamine in pro ...... r disease: a randomised trial.
@en
Efficacy of galantamine in pro ...... r disease: a randomised trial.
@nl
P2093
P1433
P1476
Efficacy of galantamine in pro ...... r disease: a randomised trial.
@en
P2093
Alexander Kurz
ChandrasekharRao Venkata Damaraju
Roger Bullock
Sean Lilienfeld
Serge Gauthier
P304
P356
10.1016/S0140-6736(02)08267-3
P407
P577
2002-04-01T00:00:00Z